TREK-1 has been shown to be involved in the maintenance of resting membrane potential, making it relevant to anesthesia and various neurological disorders, including epilepsy [41], pain [20], depression [30] and ischemia [42]. This evidence concerns the gene KCNK2 and depressive symptom measurement.